Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hideto Tamura

Showing results (1-10 of 70) with videos related to

Pageof 7
Sort By:
International Journal of Hematology|March 25, 2023
Guest Editorial: what can be done to improve cancer immunotherapies?Hideto Tamura
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|October 12, 2018
[Immunopathogenesis and appropriate use of monoclonal antibody agents in multiple myeloma]Hideto Tamura
International Journal of Hematology|January 26, 2018
Immunopathogenesis and immunotherapy of multiple myelomaHideto Tamura
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|November 1, 2016
Treatment strategy for transplant-ineligible patients with newly diagnosed multiple myelomaHideto Tamura
Nihon Rinsho. Japanese Journal of Clinical Medicine|January 29, 2015
[Single vs double stem cell transplantation for the treatment of multiple myeloma]Hideto Tamura
Leukemia Research|July 16, 2011
Disease progression mechanism in myelodysplastic syndromes: insight into the role of the microenvironmentMariko Ishibashi, Hideto Tamura, Kiyoyuki Ogata
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|December 13, 2016
Recent advances and future challenges in cancer immunotherapyNamiko Okuyama, Koji Tamada, Hideto Tamura
Cancers|January 16, 2021
Immune Functions of Signaling Lymphocytic Activation Molecule Family Molecules in Multiple MyelomaMariko Ishibashi, Rimpei Morita, Hideto Tamura
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|August 8, 2020
[SLAM family proteins as therapeutic targets in multiple myeloma]Hideto Tamura, Mariko Ishibashi, Hidemi Takahashi, et al.
Cancers|December 18, 2019
Immunotherapy for Multiple MyelomaHideto Tamura, Mariko Ishibashi, Mika Sunakawa, et al.
Pageof 7

Showing results (1-10 of 70) with videos related to

Sort By:
Pageof 7
International Journal of Hematology|March 25, 2023
Guest Editorial: what can be done to improve cancer immunotherapies?Hideto Tamura
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|October 12, 2018
[Immunopathogenesis and appropriate use of monoclonal antibody agents in multiple myeloma]Hideto Tamura
International Journal of Hematology|January 26, 2018
Immunopathogenesis and immunotherapy of multiple myelomaHideto Tamura
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|November 1, 2016
Treatment strategy for transplant-ineligible patients with newly diagnosed multiple myelomaHideto Tamura
Nihon Rinsho. Japanese Journal of Clinical Medicine|January 29, 2015
[Single vs double stem cell transplantation for the treatment of multiple myeloma]Hideto Tamura
Leukemia Research|July 16, 2011
Disease progression mechanism in myelodysplastic syndromes: insight into the role of the microenvironmentMariko Ishibashi, Hideto Tamura, Kiyoyuki Ogata
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|December 13, 2016
Recent advances and future challenges in cancer immunotherapyNamiko Okuyama, Koji Tamada, Hideto Tamura
Cancers|January 16, 2021
Immune Functions of Signaling Lymphocytic Activation Molecule Family Molecules in Multiple MyelomaMariko Ishibashi, Rimpei Morita, Hideto Tamura
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|August 8, 2020
[SLAM family proteins as therapeutic targets in multiple myeloma]Hideto Tamura, Mariko Ishibashi, Hidemi Takahashi, et al.
Cancers|December 18, 2019
Immunotherapy for Multiple MyelomaHideto Tamura, Mariko Ishibashi, Mika Sunakawa, et al.
Pageof 7